RARA CRAFT DATABASE for FDA Medical Devices
PMAP250027

FDA DEVICE FACTS

Guardant360® Liquid CDx

Guardant Health, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

PCCP: Authorized
DECISION DATEMay 19, 2026PRODUCT CODEPQP

Indications for use

Approval order for Guardant360® Liquid CDxGuardant360® Liquid CDx is a qualitative next generation sequencing-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of single nucleotide variants (SNVs) and insertions and deletions (indels) in 741 genes, copy number amplifications (CNAs) in two genes, copy number loss (CNL) in one gene, and rearrangements in nine genes. Guardant360 Liquid CDx utilizes circulating cell-free DNA (cfDNA) from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (BCTs). The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling (see approval order for Table 1).A negative result from a plasma specimen does not assure that the patient’s tumor is negative for genomic findings. Patients who are negative for the biomarkers listed in Table 1 should be reflexed to tissue biopsy testing for Table 1 biomarkers using an FDA-approved tumor tissue test, if feasible.*The efficacy of TAGRISSO (osimertinib) has not been established in the EGFR T790M plasma- positive, tissue-negative or unknown population, and clinical data for T790M plasma-positive patients are limited; therefore, testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained.Additionally, the test is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for cancer patients with solid malignant neoplasms. The test is for use with patients previously diagnosed with cancer and in conjunction with other laboratory and clinical findings.Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product.

Tables from the FDA document

Table 1. Companion Diagnostic Indications
IndicationBiomarkerTherapy
ESR1 missense mutations between codons 310 and 547ORSERDU™ (elacestrant)
ESR1 E380, V422del, S463, L469, L536, Y537, and D538 mutationsINLURIYO™ (imlunestrant)
Colorectal cancerBRAF V600EBRAFTOVI® (encorafenib) in combination with ERBITUX® (cetuximab)
EGFR exon 19 deletions, L858R, and T790M*TAGRISSO® (osimertinib)
EGFR exon 20 insertionsRYBREVANT® (amivantamab-vmjw)
KRAS G12CLUMAKRAS™ (sotorasib)
ERBB2/HER2 activating mutations (SNVs and exon 20 insertions)ENHERTU® (fam-trastuzumab deruxtecan- nxki)

Tables marked from the FDA document were reconstructed automatically. Check the original FDA document (links at the end of this page) for authoritative values.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: July 28, 2026